Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies

  • STATUS
    Recruiting
  • End date
    Jul 15, 2025
  • participants needed
    133
  • sponsor
    Sanofi
Updated on 21 July 2022
cancer
measurable disease
BRAF
KRAS
pembrolizumab
solid neoplasm

Summary

Primary Objectives:

  • Part 1
  • To characterize the safety and tolerability of SAR442720 in combination with pembrolizumab in participants with advanced solid tumors.
  • To define the MTD and RP2D for the combination of SAR442720 and pembrolizumab in participants with solid tumors.
  • Part 2
  • To determine the anti-tumor activity of SAR442720 in combination with pembrolizumab.
  • Part 3A
  • To define the MTD and RP2D for the combination of SAR442720 and adagrasib in participants with KRAS G12C NSCLC
  • To characterize the safety and tolerability of SAR442720 in combination with adagrasib in participants with KRAS G12C NSCLC
  • Part 3B
  • To determine the anti-tumor activity of SAR442720 in combination with adagrasib in participants with KRAS G12C NSCLC
  • Part 4
  • To evaluate the impact of food on the PK of SAR442720 when dosed with pembrolizumab.
  • To evaluate the impact of the formulations (formulation 1 and formulation 2) on the PK of SAR442720 when dosed with pembrolizumab.

Secondary Objectives:

  • Part 1
  • To assess the PK of SAR442720 with pembrolizumab, and the PK of pembrolizumab with SAR442720.
  • To estimate the anti-tumor effects of SAR442720 with pembrolizumab.
  • Part 2
  • To assess the safety profile of SAR442720 combined with pembrolizumab.
  • To assess other indicators of anti-tumor activity.
  • To assess the PK of SAR442720 with pembrolizumab, and the PK of pembrolizumab with SAR442720.
  • Part 3A
  • To characterize the PK of SAR442720 with adagrasib, and the PK of adagrasib with SAR442720.
  • To estimate the anti-tumor effects of SAR442720 with adagrasib
  • Part 3B
  • To assess the safety profile of SAR442720 with adagrasib in participants with KRAS G12C NSCLC.
  • To assess other indicators of anti-tumor activity.
  • To assess the PK of SAR442720 with adagrasib, and the PK of adagrasib with SAR442720.
  • Part 4
  • To assess the safety and tolerability of SAR442720 formulations with pembrolizumab
  • To estimate the anti-tumor effects of SAR442720 with pembrolizumab.

Description

This open label Phase 1 multicenter study is designed to evaluate the safety and maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SAR442720 in combination with pembrolizumab in participants with solid tumors in Part 1.

In Part 2, in the expansion cohort (Cohort A) we will assess the antitumor activity and safety of SAR442720 combined with pembrolizumab in participants with metastatic 1L lung cancer.

In Part 3, we will evaluate the safety, MTD, RP2D and antitumor activity of SAR442720 in combination with adagrasib in participants with lung cancer and KRAS G12C mutation.

In Part 4, we will evaluate the impact of the formulations (formulation 1 and formulation 2) and of the food on the PK of SAR442720 when dosed in combination with pembrolizumab. The expected duration of study intervention for participants may vary, based on progression date; median expected duration of study per participant is estimated to be about 10 months in Part 1, Part 3 and Part 4 (up to 1 month for screening, a median of 6 months for treatment, and a median of 3 months for long term follow-up) and in Part 2 16 months (up to 1 month for screening, a median of 12 months for treatment and a median of 3 months for long term follow up.)

Details
Condition Metastatic Neoplasm
Treatment Pembrolizumab, SAR442720, Adagrasib
Clinical Study IdentifierNCT04418661
SponsorSanofi
Last Modified on21 July 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Participants must be ≥ 18 years of age
Histologically proven diagnosis of advanced solid tumors
Participants must have one or more of the following molecular aberrations (Part 1): KRAS mutations and amplifications, BRAF Class 3 mutations, or NF1 LOF mutations
At least 1 measurable disease per RECIST 1.1 criteria
Participants must have following molecular aberration (Part 3A and 3B): - KRAS G12C mutation
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Woman of childbearing potential must agree to follow contraceptive guidance
Capable of giving signed informed consent

Exclusion Criteria

Predicted life expectancy <3 months
Primary central nervous system (CNS) tumors
History of cerebrovascular stroke or transient ischemic attack within previous 6 months
Symptomatic or impending cord compression. Stable CNS disease is allowed
Prior solid organ or hematologic transplant
History or current retinal pigment epithelial detachment (RPED), central serous retinopathy, retinal vascular occlusion (RVO), neovascular macular degeneration
Any clinically significant cardiac disease
Active, known or suspected autoimmune disease
History of or current interstitial lung disease or pneumonitis
Known infection with human immunodeficiency virus (HIV), known uncontrolled hepatitis B infection, active tuberculosis, or severe infection requiring parenteral antibiotic treatment
Receipt of a live-virus vaccination within 28 days, viral vaccine that do not contain live virus within 7 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted
Inadequate hematologic, hepatic and renal function
Known second malignancy
Impairment of gastrointestinal function
Any unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol
History of severe allergic reaction to any of the study intervention components
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note